CLARIO.

Oncology


World-class scientific expertise and unmatched regulatory insight combine to expedite oncology drug development

Medical imaging plays a key role in evaluating the efficacy and safety of new oncology treatments. As a sponsor, you require a solution that keeps pace with advances in oncology imaging and stays ahead of demanding timelines and budgets. Clario combines world-class scientific expertise with outstanding project management and unmatched regulatory insight to expedite oncology drug development. Clario helps reduce risk to key areas of clinical development, offering the flexibility and scalability to meet your oncology project needs. Our nearly five decades of experience include advanced capabilities in small, early-phase molecular imaging studies to large, more complex, late-phase registrational trials. Clario leads the industry with over 1,700 oncology trials, of which 100+ reached regulatory approval.

Expert independent review

Clario's independent reviewers have experience with the latest advancements in tumor response criteria, imaging modalities and oncology biomarkers, ensuring an innovative solution and world-class resources in support of oncology clinical trials with imaging endpoints. Clario's team of board-certified, sub-specialty trained radiologists, nuclear medicine physicians and medical oncologists can analyze all images from baseline through follow-up with fast turnaround times and can provide a blinded, comprehensive oncology response review.

- Sophisticated algorithms for semi-automatic, bi-dimensional and volumetric tumor measurements
- Quantitative and qualitative assessments
- Custom-designed lesion tracking for longitudinal studies
- Real-time derivation for accelerated calculations and reduced error
- Automatic transfer of image analysis data into eCRFs
- Correlation to tumor treatment intervention



Key features

Chief Medical Officer Michael Ē O'Neal, MD, leads on-staff oncologists and radiologists as well as a worldwide network of key opinion leaders Medical and scientific experts with advanced knowledge of imaging

and bone scan



Oncology project management teams with phase, indication and assessment criteria experience focused on your timelines, metrics and budgets

modalities including CT, MRI, PET



Global offices in North America, Asia and Europe



Unparalleled regulatory experience

Study and protocol design



Site imaging capability oversight and training to help ensure standardization across sites



21 CFR Part 11 and EU GDPR compliant imaging platform



Experience in operationalizing new and evolving response criteria



Real-time read monitoring for all projects

	/

Experienced medical writing professionals driving Imaging **Review Charter development** alongside internal and external experts

Clario keeps pace with advances in oncology imaging and stays ahead of demanding timelines and budgets.

Limmuno-oncology

Recent advances in personalized medicine and immunotherapies have driven an increase in immuno-oncologic drug development. Clario offers **detailed understanding** of established assessment criteria as well as extensive expertise in the application of several different approaches including **iRECIST and irRECIST**.



Cardio-oncology

As many oncology drugs have cardiotoxic side effects, studies of compounds in development oftentimes **include cardiac safety endpoints**, such as cardiac imaging (Echo and cardiac MR) as well as electrophysiology (ECG) and hemodynamic (BP) assessments. These help define the potential cardiac safety signal and benefit-risk considerations.

Regulatory leadership

Clario senior management continues to take an active leadership role in the establishment of processes, methods and counsel that **shape new regulatory guidance** for imaging endpoints. Our experts have a detailed understanding of Imaging Review Charter requirements and protocol development, adhering to recommendations and feedback from the FDA, EMA and other international regulatory agencies. We have substantial skill in supporting regulatory submissions and inspections.

Trial indication experience

Our team has experience with an array of disease indications. The breadth of experience includes single indications with single or multiple response criteria and extends to basket indications and multiple response criteria. Clario is capable of working with a wide range of response criteria.

- Acute Lymphocytic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- Bladder Cancer
- Brain Cancer
- Breast Cancer
- Chronic Lymphocytic Leukemia (CLL)
- Colorectal Cancer (CRC)
- Cutaneous Squamous Cell Carcinoma (cSCC)
- Endometrial Cancer
- Gastric Cancer
- GI Stromal Tumor
- Glioblastoma
- Head and Neck Cancer
- Hepatocellular Carcinoma
- Hodgkin's Lymphoma
- Interstitial Lung Disease
- Liver Cancer
- Melanoma
- Mesothelioma
- Multiple Myeloma
- Myelofibrosis
- Non-Hodgkin's Lymphoma (NHL)
- Non-Small Cell Lung Cancer (NSCLC)
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Renal Cell Carcinoma (RCC)
- Sarcomas
- Small Cell Lung Cancer (SCLC)
- Thyroid Cancer
- Urothelial Cancer

Molecular imaging expertise

Advances in molecular imaging enable measurement of functional changes in tumor microenvironments. Clario supports a full range of molecular imaging modalities used to identify, stage and monitor various cancers.

- ¹⁸F-fluorodeoxyglucose (FDG)
- 3'-deoxy-3'-18F-fluorothymidine (FLT)
- ¹⁸F-NaF
- ¹¹¹In-octreotide
- 123 I-metaiodobenzylguanidine (mIBG)
- 99m-Tc-MDP
- 68Ga PSMA PET and 68Ga-DOTATATE
- PSMA-PET
- PD-L1 PET

For more information, go to clario.com/contact

Tumor response criteria

Our team has expertise with conventional and advanced tumor response criteria, which take into account tumor burden, metabolism, proliferation, lipid turnover and hypoxia, providing sponsors with a wide range of oncology endpoints.

- Cheson 1999/2007
- Choi
- CNS RECIST 1.1
- EORTC
- Hallek 2008/2018
- ILD Assessment
- IMWG
- Lugano
- LYRIC
- Novel tracer diagnostic/theragnostic
- Olsen
- Owen
- PCWG2/PCWG3
- PERCIST
- Photography Assessment
- RANO/iRANO
- RECIST 1.0/1.1
- RECIL
- IRECIST
- irRECIST
- irRC
- mRECIST
- WHO Methodology
- Tumor Volume



in @clario-inc 🔰 @clario

/clarioclinical